GET DAILY SIGNALSMedifast (MED) Q3 Earnings: Revenue Falls 19.4% but Signals Q4 Profitability Turnaround
Key Takeaways
- Medifast reported third-quarter 2026 revenue of $72.05 million, down 19.4% year over year, but slightly above analyst consensus of $71.3 million.
- The company posted a GAAP net loss of $17.51 million, or $1.57 per share, versus a $2.26 million loss a year earlier, as restructuring charges weighed on results.
- Adjusted (non-GAAP) net loss narrowed to $2.1 million, or $0.19 per share, reflecting the company's Catalyst cost-reduction program.
- Management guided to a return to profitability in the fourth quarter, with EPS expected between $0.00 and $0.25.
- Active earning coaches fell 47.7% year over year to 10,200, though revenue per coach rose 54.1% to $7,064.
- Medifast ended the quarter with roughly $172.5 million in cash and investments and no debt.
Earnings Context and Why It Matters
Medifast is navigating a strategic shift from its traditional weight-management focus toward a broader metabolic-health platform centered on the Trilivy brand and MetaVantage technology. The third quarter marks an important checkpoint in that transition, as the company wrapped up major product launches and completed most of its Catalyst restructuring initiatives. From what I see, investors are monitoring whether revenue, which has held steady near $75 million for four straight quarters, can move into growth territory and whether the streamlined cost structure supports a return to positive earnings. This update also holds relevance for the broader wellness and GLP-1 weight-loss space, where Medifast is positioning its coaching and nutrition offerings as a complement rather than a direct rival to medications.
Reported Results
For the third quarter ended September 30, 2026, Medifast posted revenue of $72.05 million, a 19.4% drop from $89.41 million in the same period last year yet modestly ahead of consensus estimates of $71.3 million. The year-over-year decline stemmed mainly from fewer active earning coaches, which dropped 47.7% to 10,200.
The company recorded a GAAP net loss of $17.51 million, or $1.57 per share, compared with a $2.26 million loss, or $0.21 per share, a year earlier. The larger loss included roughly $13.8 million in Catalyst restructuring charges within selling, general, and administrative expenses. On an adjusted, non-GAAP basis, the net loss improved to $2.1 million, or $0.19 per share. Operating loss widened to $19.4 million from $4.1 million in the prior-year quarter.
Looking ahead, management guided fourth-quarter revenue between $55 million and $75 million and EPS in the range of $0.00 to $0.25, pointing to an expected return to profitability. For the full year, the company projects revenue of $280 million to $300 million and a loss per share of $1.80 to $2.05.
Market Reaction and Investor Sentiment
Medifast shares rose in early trading after the release, as investors balanced the narrower adjusted loss and upbeat fourth-quarter profitability outlook against the wider GAAP loss. The forward signal from management about returning to profitability in the fourth quarter seemed to resonate, especially given the debt-free balance sheet and roughly $172.5 million in cash and investments.
Sentiment stays measured, however. The ongoing drop in active earning coaches and the revenue contraction highlight that the turnaround remains in its early phase. I’m watching this closely to see whether the new Trilivy brand, MetaVantage products, and updated coach compensation plan can stabilize the coach base and support renewed growth.
Forward Outlook and Key Factors to Monitor
The key near-term test is whether Medifast meets its target of returning to profitability in the fourth quarter. Management’s guidance for breakeven-to-positive EPS, paired with adjusted EBITDA of $2 million to $6 million, will help gauge the effectiveness of the Catalyst cost program.
Investors should also track the path of active earning coaches. While revenue per coach has risen for four consecutive quarters, the falling coach count remains the main drag on revenue growth, so stabilizing that metric is essential for a sustained recovery.
On the product front, early uptake of the new Trilivy Reset Fuelings has been positive, with management noting that 95% of active earning coaches offered the line by September. Completing the conversion of product SKUs to the new Reset formulation by year-end could support client retention and margin trends.
Finally, the wider metabolic-health environment, including competition from GLP-1 medications and shifting consumer preferences, will influence Medifast’s ability to stand out with its coaching-led, nutrition-focused model. The company’s stance as a complement to medication-based weight loss remains a strategic point worth following in coming quarters.
Using AI Tools in My Research Process
I also checked this using Tickeron’s AI Screener to see how Medifast compares to other wellness and healthcare names on key fundamentals and technical signals. It offers a practical way to scan for similar opportunities across industries.
Exploring Tickeron’s AI Screener for Deeper Analysis
In my own workflow, I find Tickeron’s AI Screener helpful for quickly filtering stocks by technical patterns, fundamentals, and AI-driven signals. It lets me scan thousands of names with customizable criteria like industry, market cap, and performance metrics, which saves time when evaluating names like Medifast alongside peers. For anyone researching the wellness sector or building a broader watchlist, it serves as a straightforward starting point without replacing personal judgment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MED in downward trend: price may drop because broke its higher Bollinger Band on October 15, 2026
MED broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 27 similar instances where the stock broke above the upper band. In 24 of the 27 cases the stock fell afterwards. This puts the odds of success at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 51 cases where MED's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
MED moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for MED entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 13, 2026. You may want to consider a long position or call options on MED as a result. In 62 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for MED just turned positive on October 14, 2026. Looking at past instances where MED's MACD turned positive, the stock continued to rise in 41 of 58 cases over the following month. The odds of a continued upward trend are 71%.
The 10-day moving average for MED crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +0.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where MED advanced for three days, in 150 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.676) is normal, around the industry mean (7.746). MED has a moderately low P/E Ratio (-5.094) as compared to the industry average of (10.930). Projected Growth (PEG Ratio) (0.230) is also within normal values, averaging (4.440). MED's Dividend Yield (0.556) is considerably higher than the industry average of (0.081). P/S Ratio (0.416) is also within normal values, averaging (1.645).
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. MED’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MED’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of health and diet products
Industry PersonnelServices
Advertisement